2. Academic Validation
  3. Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review

Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review

  • Am J Clin Dermatol. 2025 May;26(3):307-320. doi: 10.1007/s40257-025-00928-w.
Dahyeon Kim 1,  Seanna Yang 2,  Minka Gill 3,  Nickoulet Babaei 1,  Mireya Cervantes 4,  Jashin J Wu 5
Affiliations

Affiliations

  • 1 Loma Linda University School of Medicine, Loma Linda, CA, USA.
  • 2 Tulane University School of Medicine, New Orleans, LA, USA.
  • 3 Indiana University School of Medicine, Indianapolis, IN, USA.
  • 4 Albany Medical College, Albany, NY, USA.
  • 5 Department of Dermatology, University of Miami Miller School of Medicine, 1600 N.W. 10th Avenue, RMSB, Room 2023-A, Miami, FL, 33136, USA. jashinwu@gmail.com.
PMID: 39982633 DOI: 10.1007/s40257-025-00928-w
Abstract

Innovations in biologics are transforming the treatment of psoriatic diseases. The ability to target specific levels of immune activation provides a distinct advantage. Interleukin (IL)-17 inhibitors fall into this class of biologics, and they are effectively used to treat a spectrum of psoriatic diseases, such as psoriasis vulgaris and psoriatic arthritis. In recent years, anti-IL-17 agents have been the focus of therapeutic development, with various formulations and routes of administration. In this manuscript, we review pipeline anti-IL-17 therapies for psoriatic diseases identified through a search of ClinicalTrials.gov (January 2019-December 2024) and Other databases. Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks.

Figures
Products